Abstract
As a part of the Choosing Wisely (CW) campaign aimed at reducing low-value services, the American Society of Clinical Oncology (ASCO) recommends against the use of expensive antiemetics in patients receiving a low-to-moderate emetic risk chemotherapy regimen. The objective of the study was to identify predictors of NK1-RA overuse during the post-CW era, among women with breast cancer.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call